Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 111 peer-reviewed journal articles Updated
Oncology

Validation & Orientation: Understanding Acute Lymphoblastic Leukemia (ALL)

At a Glance

Acute Lymphoblastic Leukemia (ALL) is a fast-growing blood cancer that starts in the bone marrow. While a diagnosis is overwhelming, ALL is highly treatable. Cure rates for children exceed 90%, and adult outcomes are rapidly improving with new targeted therapies and proven treatment protocols.

Receiving a diagnosis of Acute Lymphoblastic Leukemia (ALL) can feel like the world has suddenly stopped. It is completely normal to feel overwhelmed, shocked, or even paralyzed by fear [1][2]. However, while the word “leukemia” is frightening, it is important to know that you are entering a medical field that has seen some of the most remarkable success stories in modern cancer treatment [3][4].

What is ALL?

Acute Lymphoblastic Leukemia (ALL) is a type of cancer that begins in the bone marrow, the soft inner part of the bones where new blood cells are made [5]. It specifically affects lymphoid cells, which are a type of white blood cell responsible for fighting infections [6].

In a healthy body, these cells grow and divide in an orderly way. In ALL, the bone marrow starts producing immature white blood cells (called blasts) that grow uncontrollably [6]. Because these “leukemia cells” multiply so quickly, they crowd out healthy red blood cells, white blood cells, and platelets, making it difficult for the body to function normally [5]. The word “acute” means the disease progresses rapidly and requires prompt treatment [6].

(Note: You might also hear the term Lymphoblastic Lymphoma (LBL). LBL shares the exact same biology and treatment protocols as ALL, but is diagnosed when there are fewer than 20% blasts in the marrow. If you have LBL, this resource applies directly to you.)

Stabilizing Facts: Finding Your Footing

When the initial panic sets in, these facts can help provide a sense of perspective and hope:

  1. High Rates of Success in Children: ALL is the most common childhood cancer, and thanks to decades of research, the cure rate for children is now over 90% [3][4].
  2. Improving Adult Prognosis: While historical survival rates for adults have been lower, this narrative is rapidly changing [7]. Doctors now use “pediatric-inspired” protocols for younger adults, alongside new targeted therapies and immunotherapies, which are significantly improving survival and providing more options than ever before [8][9].
  3. A Clear Roadmap: Because ALL is well-studied, doctors use highly structured, proven treatment “protocols.” You are not a “guinea pig”; you are following a roadmap that has been refined over years to be as effective as possible [6][10].

Incidence and Who it Affects

ALL follows a unique pattern across different ages:

  • Children: It is most frequently diagnosed in children under age 5 [11].
  • Adolescents & Young Adults (AYA): This group (typically ages 15–39) often receives treatments similar to those given to children, as these have been shown to provide better disease control and long-term survival [8][12].
  • Adults: While less common in older adults, new targeted therapies (drugs that attack specific markers on cancer cells) and immunotherapies are transforming the standard of care [9][13].

Preparing for the Journey

In the coming days, your medical team will perform “risk stratification” [6]. This means they will look at the specific DNA of the leukemia cells to tailor the treatment specifically to you or your child [14][15].

Important note before starting treatment: It is critical to ask your care team about fertility preservation (such as freezing eggs or sperm). The intensive chemotherapy used for ALL can impact future fertility, and this conversation should happen as early as possible [16].

Explore the Resource Guide

01

The Biology of ALL: Subtypes and Genetic Markers

Learn about Acute Lymphoblastic Leukemia (ALL) subtypes and genetic markers. Understand B-cell, T-cell, Ph+ status, and what they mean for your treatment.

02

Pathology & Testing: Understanding Your Reports and MRD

Learn how to read your Acute Lymphoblastic Leukemia (ALL) pathology report. Understand blast counts, cytogenetics, and what MRD-negative means for treatment.

03

The Treatment Journey: Phases of Care and Protecting the Brain

Learn the phases of Acute Lymphoblastic Leukemia (ALL) treatment. Understand induction, consolidation, maintenance therapy, and CNS prophylaxis.

04

Standard of Care: Chemotherapy, Targeted Pills, and Immunotherapy

Discover the standard treatments for Acute Lymphoblastic Leukemia (ALL), including pediatric-inspired chemo regimens, targeted TKIs, and advanced immunotherapy.

05

Survivorship: Monitoring and Life After Maintenance

Learn what to expect during ALL survivorship. Understand post-treatment monitoring, MRD testing, potential late effects, and how to manage scan anxiety.

Common questions in this guide

What is Acute Lymphoblastic Leukemia (ALL)?
ALL is a fast-growing cancer that starts in the bone marrow, where new blood cells are made. It causes the body to produce too many immature white blood cells, which crowd out healthy cells and make it hard for the body to function properly.
What is the difference between ALL and Lymphoblastic Lymphoma (LBL)?
LBL and ALL share the exact same biology and are treated with the same medical protocols. The main difference is that LBL is diagnosed when there are fewer than 20% leukemia cells (blasts) found in the bone marrow.
Is Acute Lymphoblastic Leukemia curable?
Yes, ALL is highly treatable and curable. In children, the cure rate is over 90%. Survival rates for adults are also improving significantly thanks to new targeted therapies, immunotherapies, and the use of pediatric-inspired treatment protocols.
Should I ask my doctor about preserving my fertility before ALL treatment?
Yes, it is critical to ask your care team about fertility preservation, such as freezing eggs or sperm, before starting therapy. The intensive chemotherapy used to treat ALL can impact future fertility, so this conversation should happen as early as possible.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my (or my child's) specific subtype of ALL, such as B-cell or T-cell?
  2. 2.Based on age and initial blood counts, is this considered a 'standard risk' or 'high risk' case?
  3. 3.What are my options for fertility preservation, and who can I speak to about this immediately?
  4. 4.How does the hospital's experience with pediatric-inspired protocols for AYAs or adults impact the treatment plan?
  5. 5.Can you connect me with a social worker or patient navigator who specializes in leukemia to help manage the emotional and logistical stress?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Behavioral symptoms and psychiatric disorders in child and adolescent long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.

    Liu W, Cheung YT, Brinkman TM, et al.

    Psycho-oncology 2018; (27(6)):1597-1607 doi:10.1002/pon.4699.

    PMID: 29521470
  2. 2

    Behavioral and Emotional Functioning of Children and Adolescents at the End of Treatment for Acute Lymphoblastic Leukemia Compared to Healthy Peers.

    De Luca CR, Mulraney M, Anderson V, et al.

    Journal of clinical psychology in medical settings 2022; (29(2)):421-431 doi:10.1007/s10880-021-09840-x.

    PMID: 35113314
  3. 3

    Acute Lymphoblastic Leukemia in Children.

    Hunger SP, Mullighan CG

    The New England journal of medicine 2015; (373(16)):1541-52 doi:10.1056/NEJMra1400972.

    PMID: 26465987
  4. 4

    Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

    Schmiegelow K, Müller K, Mogensen SS, et al.

    F1000Research 2017; (6()):444 doi:10.12688/f1000research.10768.1.

    PMID: 28413626
  5. 5

    The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

    Vicente C, Cools J

    Haematologica 2015; (100(11)):1373-5 doi:10.3324/haematol.2015.136077.

    PMID: 26521295
  6. 6

    Immunological Subtypes of Acute Lymphoblastic Leukemia- Beyond Morphology: Experience from Kidwai State Cancer Institute, Bengaluru, India.

    Rajkumar NN, Vijay RH

    The Journal of the Association of Physicians of India 2017; (65(7)):14-17.

    PMID: 28792162
  7. 7

    L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.

    Egler RA, Ahuja SP, Matloub Y

    Journal of pharmacology & pharmacotherapeutics 2016; (7(2)):62-71 doi:10.4103/0976-500X.184769.

    PMID: 27440950
  8. 8

    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

    Siegel SE, Advani A, Seibel N, et al.

    American journal of hematology 2018; (93(10)):1254-1266 doi:10.1002/ajh.25229.

    PMID: 30058716
  9. 9

    Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

    Kantarjian H, Ravandi F, Short NJ, et al.

    The Lancet. Oncology 2018; (19(2)):240-248 doi:10.1016/S1470-2045(18)30011-1.

    PMID: 29352703
  10. 10

    A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.

    Capria S, Molica M, Mohamed S, et al.

    Expert review of hematology 2020; (13(7)):755-769 doi:10.1080/17474086.2020.1770591.

    PMID: 32419532
  11. 11

    Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012.

    Hubbard AK, Spector LG, Fortuna G, et al.

    JNCI cancer spectrum 2019; (3(1)):pkz007 doi:10.1093/jncics/pkz007.

    PMID: 30984908
  12. 12

    Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.

    Jaime-Pérez JC, Jiménez-Castillo RA, Pinzón-Uresti MA, et al.

    Pediatric blood & cancer 2017; (64(7)) doi:10.1002/pbc.26396.

    PMID: 27957789
  13. 13

    Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

    Stein AS, Kantarjian H, Gökbuget N, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(8)):1498-1504 doi:10.1016/j.bbmt.2019.04.010.

    PMID: 31002989
  14. 14

    Therapy-related acute lymphoblastic leukemia.

    Ribera JM

    Haematologica 2018; (103(10)):1581-1583 doi:10.3324/haematol.2018.200311.

    PMID: 30270204
  15. 15

    Recent research on the association between signal transducer and activator of transcription 5 and childhood acute lymphoblastic leukemia.

    Duan YF, Wen FQ

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2022; (24(8)):942-947 doi:10.7499/j.issn.1008-8830.2203117.

    PMID: 36036135
  16. 16

    MYC degradation via AURKB inhibition: a new brake in the path to T-ALL.

    Zhang W, Pear WS

    Blood science (Baltimore, Md.) 2020; (2(2)):68-69 doi:10.1097/BS9.0000000000000046.

    PMID: 35402818

This page provides a general overview of Acute Lymphoblastic Leukemia for educational purposes. Always discuss your specific diagnosis, risk factors, and treatment plan with your oncologist.

Get notified when new evidence is published on Acute lymphoblastic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.